Immunomodulatory drug treatment in multiple sclerosis

References

• Lassmann H. Bruck W, Lucchinetti F. The immunopathology of MS: an overview. Brain Pathol.17, 210–218 (2007).
   PubMed Web of Science ®Google Scholar
• Murray TJ. The history of multiple sclerosis: the changing frame of the disease over the centuries. J. Neuro. Sci.277(Suppl. 1), S3–S8 (2009).
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Wekerle H. Autoimmune concepts of MS as a basis for selective immunotherapy: from the pipe dreams to therapeutic pipelines. Proc. Natl Acad. Sci. USA101, 14599–14606 (2004).
   PubMed Web of Science ®Google Scholar
• Lassmann H. Mechanisms of Inflammation induced tissue injury in multiple sclerosis. J. Neuro. Sci.274, 45–47 (2008).
   PubMed Web of Science ®Google Scholar
• Holmoy T. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Minerva Med.99, 119–140 (2008).
   PubMedGoogle Scholar
• Hemmer B, Nessler S, Zhou D. Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract.2(4), 201–211 (2006).
   Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain132, 1175–1189 (2009).
   PubMed Web of Science ®Google Scholar
• Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Methods Mol. Biol.549, 157–173 (2009).
   PubMedGoogle Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disease. Ann. Rev. Neurosci.31, 247–269 (2008).
   PubMed Web of Science ®Google Scholar
• Bruck W. Evidence for primary neurodegeneration in MS. Mult. Scler. (Suppl. 1), S9, 13 (2008).
   Google Scholar
• Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol.7(9), 841–851 (2008).
   PubMed Web of Science ®Google Scholar
• Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exper. Neurol. DOI: 10.1016/j.expneurol.2009.11.019 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Johnson KP, Knobler RL, Greenstein JL et al. Recombinant β interferon treatment of relapsing–remitting multiple sclerosis pilot study results. Neurology40(Suppl. 1), 261 (1990).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaboration Group (MSCRG). Ann. Neurol.39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• PRIM (Prevention of relapses and disability by interferon β-1a subsequently in multiple sclerosis) study group. Randomized, double blind, placebo controlled study of Interferon β-1a in relapsing–remitting multiple sclerosis: chemical results. Lancet352, 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Meshorer M, Hirshfeld T, Sela M, Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol.1, 242–248 (1971).
   PubMed Web of Science ®Google Scholar
• Revel M, Chebath J, Mangelus M et al. Antagonsim of interferon β in interferon γ: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult. Scler.1, S5–S11 (1995).
   PubMedGoogle Scholar
• Clerico M, Contessa G, Durelli L. Interferon-β1a for the treatment of multiple sclerosis. Expert. Opin. Biol. Ther.7, 535–542 (2007).
   PubMed Web of Science ®Google Scholar
• Markowitz CE. Interferon-β: mechanism of action and dosing issues. Neurology68, S8–S11 (2007).
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralizing antibodies against interferon β in patients with relapsing–remitting multiple sclerosis. Lancet362, 1184–1161 (2003).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B et al Neutralizing antibodies to interferon β: assessment of their clinical and radiographic impact. An evidence report to the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology68(13), 977–984 (2007).
   PubMed Web of Science ®Google Scholar
• Ebers G. The interferon β-1b 16-year long-term follow-up study: the final results. Neurology66, A32 (2006).
   Web of Science ®Google Scholar
• Fridkis-Hareli M, Teitelbaum D, Gurevich E et al. Direct binding of myelin basic protein and synthetic copolymer 1 class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc. Natl Acad. Sci. USA91, 4872–4876 (1994).
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod’homme T, Youssef S et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Med.13(8), 935–943 (2007).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Sela M. Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA94, 10821–10826 (1997).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Farina C, Yassouridis A. Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl Acad. Sci. USA97, 7452–7457 (2000).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate specific T-cells in the brain express TH2/3 cytokines and brain-derived neurotrophic factor in situ.Proc. Natl Acad. Sci. USA100(24), 14157–14162 (2003).
   PubMed Web of Science ®Google Scholar
• Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult. Scler.14(6), 749–758 (2008).
   PubMed Web of Science ®Google Scholar
• Jee Y, Piao WH, Liu R et al. CD4+CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin. Immunol.125, 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Begum-Haque S, Sharma, A, Kasper I et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol.204, 58–65 (2008).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Stock A et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing–remitting or chronic EAE. J. Neuroimmunol. DOI: 10.1016/j.jneuroim.2010.04.022 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-labeled study of glatiramer acetate. Mult. Scler.16(3), 342–350 (2010).
   PubMed Web of Science ®Google Scholar
• Berger T. Current therapeutic recommendations in multiple sclerosis. J. Neurol. Sci.287(Suppl. 1), S37–S45 (2009).
   PubMed Web of Science ®Google Scholar
• Pilz G, Wipfler P, Ladurner G, Kraus J. Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discov. Today13, 1013–1025 (2008).
   PubMed Web of Science ®Google Scholar
• Vosoughi R, Freedman M. Therapy of MS. Clin. Neurol. Neurosurg.112(5), 365–385 (2010).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol.49(3), 290–297 (2001).
   PubMed Web of Science ®Google Scholar
• Rio J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Interferon β in relapsing–remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol.252(7), 795–800 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold DL, Campagnolo D, Panitch H, et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J. Neurol.255(10), 1473–1478 (2008).
   PubMed Web of Science ®Google Scholar
• Leary SM, Porter B. Thompson A. Multiple diagnosis and management of acute relapses. Postgrad. Med. J.81, 302–308 (2005).
   PubMed Web of Science ®Google Scholar
• Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet338, 1051–1055 (1991).
   PubMed Web of Science ®Google Scholar
• Filder JM, Dejoy SQ, Gibbons JJ Jr. Selective immunomodulation by the anti-neoplastic agent mitoxantrone, suppression of B lymphocyte function. J. Immunol.137(2), 727–732 (1986).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int. MS J.12, 74–87 (2005).
   PubMedGoogle Scholar
• Gold R. Combination therapies in multiple sclerosis. J. Neurol.255, 51–60 (2008).
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis: mechanism and rationale. Neurology64(8), 1336–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Kappos L. Natalizumab: targeting α4-integrins in multiple sclerosis. Neurodegener. Dis.5(1), 16–22 (2008).
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol.9(4), 438–446 (2010).
   PubMed Web of Science ®Google Scholar
• Kieseier B, Wiendl H, Hartung HP, Stuve O. The future of multiple sclerosis therapy. Pharmacol. Res.60, 207–211 (2009).
   PubMed Web of Science ®Google Scholar
• Gasperini C, Ruggierir S. New oral drugs for multiple sclerosis. Neurol. Sci.30(2), S170–S183 (2009).
   Web of Science ®Google Scholar
• Rammohan K, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology74, S47–S53 (2010).
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptor. J. Biol Chem.277, 21453–21473 (2002).
   PubMed Web of Science ®Google Scholar
• Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptor. Phamacol. Ther.108, 308–319 (2005).
   PubMed Web of Science ®Google Scholar
• Budde K, Schomouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Neprol.13, 1073–1083 (2002).
   PubMed Web of Science ®Google Scholar
• Webb M, Tham CS, Lin FF et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalomyelitis in SJL mice. J. Neuroimmunol.153, 108–121 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Beutler E. Cladribine (2-chlorodeoxyadenine). Lancet340, 952–956 (1992).
   PubMed Web of Science ®Google Scholar
• Sipe LC. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother.5, 721–727 (2005).
   PubMedGoogle Scholar
• Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribin. Proc. Natl Acad. Sci. USA93(4), 1716–1720 (1996).
   PubMed Web of Science ®Google Scholar
• Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann. Pharmacother.40(10), 1814–1821 (2006).
   PubMed Web of Science ®Google Scholar
• Rice GPA, Filippi M, Comi G. Cladribine and progressive MS. Clinical and MRI outcomes of multicenter controlled trial. Neurology54(5), 1145–1155 (2000).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 416–426 (2010).
   PubMed Web of Science ®Google Scholar
• Nakajima A, Yamanaka H, Kamatani N. Leflunomid: clinical effectiveness and mechanism of action. Clin. Calcium13(6), 771–775 (2003).
   PubMedGoogle Scholar
• Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor κB activation and gene expression. J. Immunol.162, 2095–2102 (1999).
   PubMed Web of Science ®Google Scholar
• Korn T, Toyka K, Hartung HP et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain124, 1791–1802 (2001).
   PubMed Web of Science ®Google Scholar
• Merrill JE, Hanak S, Pu SF et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J. Neurol.256(1), 89–103 (2009).
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66, 894–900 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman M, Wolinsky JS, Byrnes WJ. Oral teriflunomide or placebo added to Interferon-β for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at: European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting. Düsseldorf, Germany, September 2009.
   Google Scholar
• Mrowietz U, Asadullan K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med.11(1), 43–48 (2005).
   PubMed Web of Science ®Google Scholar
• De Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol.26(9), 2067–2074 (1996).
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol.121(6), 1383–1388 (2003).
   PubMed Web of Science ®Google Scholar
• Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun.236(2), 313–322 (1997).
   PubMed Web of Science ®Google Scholar
• Lakashev M Zeng W, Goetz S et al. Activation of Nrf2 and modulation of disease progression in EAE model by BG00012 (dimethylfumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modulities. Mult. Scler.13(2), 503 (2007).
   Google Scholar
• Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet372, 1463–1472 (2008).
   PubMed Web of Science ®Google Scholar
• Jönsson S, Andersson G, Fex T et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure–activity relationship. J. Med. Chem.47(8), 2075–2088. (2004).
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol.130, 163–172 (2002).
   PubMed Web of Science ®Google Scholar
• Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol.156(1–2), 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology64, 987–991 (2005).
   PubMed Web of Science ®Google Scholar
• Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet371, 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol.3(12), 744–751 (2004).
   PubMed Web of Science ®Google Scholar
• Metz LM, Zhang Y, Yeung M et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol.55(5), 756 (2004).
   PubMed Web of Science ®Google Scholar
• Metz LM, Li D, Traboulsee A et al. Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult. Scler.15(10), 1183–1194 (2009).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with Interferon-β 1b in MS. Neurology59(7), 990–997 (2002).
   PubMed Web of Science ®Google Scholar
• Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature420(6911), 78–84 (2002).
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing–remitting multiple sclerosis. Lancet363, 1607–1608 (2004).
   PubMed Web of Science ®Google Scholar
• Paul F, Waiczies S, Wuerfel J et al. Oral high dose atrvastatin treatment in relapsing–remitting multiple sclerosis. PLoS One3(4), e1928 (2008).
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining β interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology71(18), 1390–1395 (2008).
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet2(8625), 1394–1399 (1988).
   PubMed Web of Science ®Google Scholar
• Cobbold SP, Hale G, Clark MR, Waldmann H. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms. Prog. Clin. Biol. Res.333, 139–151; discussion 152–154 (1990).
   PubMedGoogle Scholar
• Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol.253(1), 98–108 (2006).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359(17), 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90(6), 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• McFarland HF. The B cell – old player, new position on the team. N. Engl. J. Med.358(7), 664–665 (2008).
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol.180, 63–70 (2006).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N.Engl. J. Med.358(7), 676–688 (2008).
   Google Scholar
• Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener. Dis.5(1), 23–26 (2008).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA103(15), 5941–5946 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman MD, Wynn DR, Montalban X. A Phase 2 randomized double-blind placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody in patients with active relapsing forms of multiple sclerosis: week 44 results. Neurology70(Suppl. 1), A220 (2008).
   Google Scholar
• Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther. Clin. Risk Manag.6, 59–63 (1020).
   Google Scholar
• Correa FG, Mestre L, Docagne F, Borreli J, Guaza C. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam. Hom.81, 207–225 (2009).
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr. Pharm. Des.14(23), 2326–2336 (2008).
   PubMed Web of Science ®Google Scholar
• De Lago E, Fernandez-Ruiz J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol. Disord. Drug Targets6(6), 377–387 (2007).
   PubMedGoogle Scholar
• Cencioni MT, Chiurchiù V, Catanzaro G et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PloS One5, 1–10 (2010).
   Web of Science ®Google Scholar
• Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int. Rev. Immunol.24, 393–413 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science259, 1321–1324 (1993).
   PubMed Web of Science ®Google Scholar
• Panitch H, Hrancic G, Oral myelin Group. Clinical results of Phase III trial in of oral myelin in relapsing remitting multiple sclerosis. Ann. Neurol.42, 467 (1997).
   Google Scholar
• Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol.13(8), 887–895 (2006).
   PubMed Web of Science ®Google Scholar
• Correale J, Farez M, Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs22(3), 175–198 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med.6(10), 1176–1182 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature292, 60–61 (1981).
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Bar-Or A. Antigen-specific therapies in multiple sclerosis. Expert Opin. Emerg. Drugs14(3), 551–560 (2009).
   PubMed Web of Science ®Google Scholar
• Pluchino S, Quattrini A, Brambilla E et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature422(6933), 688–694 (2003).
   PubMed Web of Science ®Google Scholar
• Einstein O, Grigoriadis N, Mizrachi-Kol R et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp. Neurol.198(2), 275–284 (2006).
   PubMed Web of Science ®Google Scholar
• Karussis D, Kassis I, Kurkalli B, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): Aproposed treatment for multiple sclerosis and other neuroimmunological neurodegenerative diseases. J. Neurol. Sci.265, 131–135 (2008).
   PubMed Web of Science ®Google Scholar
• Freedman MS, Bar-Or A, Atkins HL et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult. Scler.16(4), 503–510 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao RC, Liao L, Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J. Lab. Clin. Med.143(5), 284–291 (2004).
   PubMedGoogle Scholar
• Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol.7(7), 626–636 (2008).
   PubMed Web of Science ®Google Scholar
• Fassas A, Mancardi GL. Autologous hemapoietic stem cell transplantation for multiple sclerosis: Is it worthwhile? Autoimmunity28, 1 (2008).
   Web of Science ®Google Scholar
• Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by heamatopoietic stem cell transplantation. Mult. Scler.15(2), 229–237 (2009).
   PubMed Web of Science ®Google Scholar
• Vajda FJE. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci.9(1), 4–8 (2002).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Arnon R. Linkage between immunomodulation neuroprotection and neurogeneisis. Drug News Perspect.22(6), 301–313 (2009).
   PubMed Web of Science ®Google Scholar
• Aktas O, Kieseier B, Hartung AP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosci.33(3), 145–152 (2010).
   Web of Science ®Google Scholar
• Traynor K. Dalfampridine approved for MS. Am. J. Health Sys. Pharm.67(5), 335 (2010).
   PubMed Web of Science ®Google Scholar
• Biernacki K, Antel JP, Blain M et al. Interferon β promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol.62(4), 563–568 (2005).
   PubMed Web of Science ®Google Scholar
• Malik O, Compston DA, Scolding NJ. Interferon-β inhibits mitogen induced astrocyte proliferation in vitro. J. Neuroimmunol.86(2), 155–162 (1998).
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Hartung HP. Interferon-β and neuroprotection in multiple sclerosis – facts, hopes and phantasies. Exp. Neurol.10, 1–4 (2007).
   Web of Science ®Google Scholar
• Sättler MB, Demmer I, Williams SK et al. Effects of Interferon-β-1a on neuronal survival under autoimmune inflammatory conditions. Exp. Neurol.201(1), 172–181 (2006).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology53(8), 1698–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Narayanan S, De Stefano N, Francis GS et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b. J. Neurol.248(11), 979–986 (2001).
   PubMed Web of Science ®Google Scholar
• Parry A, Clare S, Jenkinson M, Smith S, Palace J. Matthews PM. MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex. J. Neuroimaging13(3), 234–239 (2003).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eylam R, Domev H, Labunsky G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl Acad. Sci. USA102, 19045–19050 (2005).
   PubMed Web of Science ®Google Scholar
• Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol.167, 215–218 (2005).
   PubMed Web of Science ®Google Scholar
• Maier K, Kuhnert AV, Taheri N et al. Effects of glatiramer acetate and Interferon-β on neurodegeneration in a model of multiple sclerosis: a comparative study. Am. J. Pathol.169(4), 1353–1364 (2006).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neuroscience25(36), 8217–8228 (2005).
   PubMed Web of Science ®Google Scholar
• Aharoni R, Herschkovitz A, Eilam R. et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis.Proc. Natl Acad. Sci. USA105(32), 11358–11363 (2008).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Rocca MA. Glatiramer Acetate reduces the proportion of new MS lesions evolving into ‘black holes’. Neurology57, 731–733 (2001).
   PubMed Web of Science ®Google Scholar
• Khan O, Shen Y, Caon C et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing–remitting multiple sclerosis. Mult. Scler.11, 646–651 (2005).
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol.3(2), 153–167 (2008).
   PubMedGoogle Scholar
• Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia57(2), 182–193 (2009).
   PubMed Web of Science ®Google Scholar
• DeAngelis T, Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J. Med.75(2), 157–167 (2008).
   PubMed Web of Science ®Google Scholar
• Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegener. Dis.4, 443–486 (2007).
   PubMed Web of Science ®Google Scholar